While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.
Many investors, especially more aggressive traders, look at lower-priced stocks as a way not only to make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.
[in-text-ad]
Skeptics of low-priced shares should remember that at one point both Amazon, Apple and Netflix traded in the single digits. One stock we featured over the years, Zynga, was purchased by Take-Two Interactive. Cogent Biosciences, which we featured in March, has tripled since then.
Raymond James is one the premier investment banks in the world, so we screened the firm’s outstanding research database and found five stocks trading under the $10 level with the firm’s highest Strong Buy rating that could provide investors with some huge upside potential, ranging from 85% to almost 400%. Note that these five stocks are much better suited for very aggressive investors. It is also important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.
Byrna Technologies
In a very dangerous and litigious world, this stock could be a huge winner. Byrna Technologies Inc. (NASDAQ: BYRN) is a defense technology company that develops and manufactures less-lethal munitions.
The company offers a Byrna line of handheld personal security devices, including the Byrna SD and Byrna SD .68 caliber handheld personal security devices that are designed to be used by civilians and private security professionals, as well as Byrna HD magazines, shoulder-fired launchers and projectiles.
Byrna Technologies also offers accessories and related safety products, including the Byrna Banshee, Byrna Shield, compressed carbon dioxide canisters, sighting systems, holsters and Byrna-branded apparels. It operates in the United States and South Africa. The company was formerly known as Security Devices International and changed its name in March 2020.
The Raymond James price target is $15 and the consensus target is $13. The shares last traded on Friday at $8.26. Hitting the Raymond James target price would be an 85% gain.
24/7 Wall St.InflaRX
This micro-cap biotech could be a massive winner for aggressive traders. InflaRx N.V. (NASDAQ: IFRX) discovers and develops inhibitors using C5a technology, primarily in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.
InflaRx’s lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase 3 clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. It is in a Phase 2 trial for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease; a Phase 2a exploratory study to treat pyoderma gangraenosum, a chronic inflammatory skin disorder; and in Phase 2 for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.
[in-text-ad]
The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology and clinical trial collaboration and supply agreement with Merck.
Raymond James has an $8.12 price target. The consensus target is $5.50, and shares closed on Friday at $2.55. Hitting the Raymond James target would be a 232% gain.
24/7 Wall St.Ocular Therapeutics
This micro-cap biopharmaceutical company could really be a big winner with an aging population. Ocular Therapeutics Inc. (NASDAQ: OCUL) focuses on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery. Its Dextenza is a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant that is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
The company has a strategic collaboration with Regeneron Pharmaceuticals for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases. It has a strategic collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC. And it has a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD).
The $14 Raymond James target price compares with a $13.29 consensus target. The stock last traded on Friday at $2.98. A move to the target would be a 370% gain.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
